Document Detail


Low-dose UVA(1) phototherapy for scleroderma: what benefit can we expect?
MedLine Citation:
PMID:  21635565     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Background  The first reports of the application of ultravioletA(1) (UVA(1) ) phototherapy for scleroderma go back only to 1995, but since then, several studies have proven its effectiveness in this disease. Objectives  To evaluate the effectiveness of low-dose (35 J/cm(2) ) UVA(1) phototherapy in patients with scleroderma, trying to define the subgroups that benefit most from this treatment. Methods  Retrospective analysis of patients diagnosed with clinical and/or histological scleroderma, undergoing low-dose UVA(1) phototherapy between 2003 and 2010. Results  We studied 21 patients (20 women and one man) aged 10-75 years (mean 50). Eighteen with morphea performed a total of 29 treatments, with an average of 33 sessions per treatment per patient, a mean dose of 31 J/cm(2) per session and an average cumulative dose of 1662 J/cm(2) (310-4270). The three patients with systemic scleroderma underwent a total of five treatments, with an average of 26 sessions per treatment per patient, a mean dose of 29.5 J/cm(2) per session and an average cumulative dose of 1160 J/cm(2) (660-1695). Using the modified Rodnan skin score, in the group of patients with morphea, a marked improvement was found in 77.8% patients and a moderate improvement was found in 11.1% patients. In the systemic scleroderma group, a patient with complete remission of the skin sclerosis is emphasized. Conclusions  Our experience allows us to conclude that low-dose UVA(1) phototherapy is a well tolerated option, with excellent results mainly in patients with morphea. This treatment is a valuable contribution to these patients, given the limited therapeutic options available.
Authors:
N Pereira; F Santiago; H Oliveira; A Figueiredo
Related Documents :
18376455 - Current evidence on prevention and management of contrast-induced nephropathy.
21508885 - Ultrasonographic evaluation of risser's sign; is it a reliable and reproducible method?
21420185 - Assessment of the structural remodeling of the left atrium by 64-multislice cardiac ct:...
60025 - Plasma concentrations of griseofulvin in healthy volunteers and out-patients treated fo...
20186715 - Body schema and self-representation in patients with bulimia nervosa.
7206005 - Serum cpk isoenzyme bb as an indicator of brain tissue damage following head injury.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-6-3
Journal Detail:
Title:  Journal of the European Academy of Dermatology and Venereology : JEADV     Volume:  -     ISSN:  1468-3083     ISO Abbreviation:  -     Publication Date:  2011 Jun 
Date Detail:
Created Date:  2011-6-3     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9216037     Medline TA:  J Eur Acad Dermatol Venereol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2011 The Authors. Journal of the European Academy of Dermatology and Venereology © 2011 European Academy of Dermatology and Venereology.
Affiliation:
Department of Dermatology, Coimbra University Hospital, Coimbra, Portugal.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Receptor dependent immobilization of spermatozoa by sperm immobilization factor isolated from Escher...
Next Document:  Contribution of P2X7 1513A/C loss-of-function polymorphism to extrapulmonary tuberculosis susceptibi...